{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280757","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.599122+00:00","generated_at":"2026-06-22T01:02:59.122910+00:00","sec_items":["2.02","9.01","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aadi Bioscience Q3 revenue $4.2M; Desai to Executive Chairman, Delaney named CEO","bullets":["Net product sales of FYARRO $4.2M in Q3 2022, up 24% from Q2; net loss $14.5M (vs $87.1M in Q3 2021).","Cash $183M as of Sep 30, 2022; cash runway extended into 2025 after $72.5M PIPE financing.","Founder/CEO Neil Desai appointed Executive Chairman; COO Brendan Delaney succeeds as President & CEO effective Jan 1, 2023.","Delaney receives $624K base salary, 60% bonus target, option for 150K shares; Board expanded to 8.","PRECISION 1 trial on track for preliminary data H1 2023; Mirati collaboration on adagrasib/nab-sirolimus combo expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280757","json":"https://secwatch.observer/filing/0001193125-22-280757.json","markdown":"https://secwatch.observer/filing/0001193125-22-280757.md","text":"https://secwatch.observer/filing/0001193125-22-280757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/d317786d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:02:59.122910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2358f7802d71434c1df67ddbaee74666bbf8e26c","claim":"Whitehawk Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million, net income Net loss for the three months ended September 30, 2022 was $14.5 million.","evidence_excerpt":"data in the first half of 2023. • Grew FYARRO net product sales . For the three months ended September 30, 2022, net product sales of FYARRO showed continued growth, ending with $4.2 million in sales in the third quarter, a 24% increase over the second quarter. • Leadership transition. Current CEO, Dr. Neil Desai, has been appointed Executive Chairman,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$4.2 million"},{"label":"Net income","value":"Net loss for the three months ended September 30, 2022 was $14.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"386eabbf76","claim":"Brendan Delaney was elected as Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the Board increased the Board’s size from seven (7) to eight (8) directors and elected Mr. Delaney to fill the resulting vacancy, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4613aa45e9","claim":"Brendan Delaney was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"and Brendan Delaney, Chief Operating Officer, to President and Chief Executive Officer of the Company, effective as of January 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ffe00c9d4a","claim":"Neil Desai was appointed as Executive Chairman at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the appointment of Neil Desai, founder, director, President and Chief Executive Officer of the Company, to Executive Chairman of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}